AlphaMark Advisors LLC Trims Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

AlphaMark Advisors LLC reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 92.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 286 shares of the medical equipment provider’s stock after selling 3,292 shares during the quarter. AlphaMark Advisors LLC’s holdings in Lantheus were worth $26,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the 3rd quarter valued at about $25,000. Signaturefd LLC lifted its holdings in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the period. Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus in the third quarter worth $51,000. Finally, GAMMA Investing LLC raised its position in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by insiders.

Lantheus Price Performance

Shares of LNTH opened at $97.50 on Monday. The stock has a market capitalization of $6.78 billion, a price-to-earnings ratio of 16.22 and a beta of 0.46. Lantheus Holdings, Inc. has a 1 year low of $50.42 and a 1 year high of $126.89. The business’s 50 day simple moving average is $91.11 and its 200-day simple moving average is $100.53.

Analysts Set New Price Targets

A number of brokerages have issued reports on LNTH. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. Truist Financial reiterated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.